Ironwood Pharmaceuticals to Attend Citizens JMP Life Sciences Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) has announced its participation in a fireside chat at The Citizens JMP Life Sciences Conference. This event will take place on Monday, May 13, 2024, at 10:00 a.m. ET at the New York Hilton Midtown. Those interested can listen to a live audio webcast of the discussion via the Investors section of Ironwood’s website. To ensure a smooth experience, it is recommended to log on approximately 15 minutes before the start time for any necessary software downloads. For those who cannot attend the live event, a replay of the webcast will be available on Ironwood’s website for a year following the conference.

Ironwood Pharmaceuticals, a company listed on the Nasdaq stock exchange under the ticker IRWD, is part of the S&P SmallCap 600®. The company is a prominent player in the gastrointestinal (GI) healthcare sector, dedicated to improving treatments for GI diseases and setting new standards of care for patients. Ironwood is notably recognized for developing LINZESS® (linaclotide), which leads the U.S. branded prescription market for adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Additionally, LINZESS is approved for treating functional constipation in pediatric patients aged 6-17 years.

Ironwood's innovation extends beyond LINZESS. The company is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog. This therapeutic agent is being developed to treat rare gastrointestinal conditions, such as short bowel syndrome with intestinal failure (SBS-IF). Ironwood is also working on several early-stage assets, demonstrating its ongoing commitment to GI disease research and patient care.

Founded in 1998, Ironwood Pharmaceuticals has its headquarters in Boston, Massachusetts, and an additional site in Basel, Switzerland. The company emphasizes transparency and regularly updates investors with relevant information on its website. Moreover, Ironwood maintains an active presence on social media platforms such as Twitter and LinkedIn, ensuring stakeholders stay informed about the company's latest developments.

Ironwood Pharmaceuticals' dedication to GI healthcare and continuous innovation places it at the forefront of the industry, striving to alleviate the burden of GI diseases and meet the significant unmet needs of patients.